Clinical Trial

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Name: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — clinical trial record (NCT05740566)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DeLLphi-304

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Trial Details

NCT Number	NCT05740566
Lead Sponsor	Amgen
Conditions	Small Cell Lung Cancer (SCLC)
Enrollment	509 participants
Start Date	2023-05-31
Primary Completion	2025-01-29 (estimated)
Study Completion	2028-03-26 (estimated)
Updated on ClinicalTrials.gov	2026-01-05